Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group... por Yair Herishanu, Neta Goldschmidt, Osnat Bairey, Rosa Ruchlemer, Riva Fineman, Naomi Rahimi-Levene, Lev Shvidel, Tamar Tadmor, Aviv Ariel, Andrea Braester, Mika Shapiro, Erel Joffe, Aaron Polliack, on behalf of the Israeli CLL Study Group

Ligazón do recurso